These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 22908905)

  • 1. Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia.
    Dahl E; Gluud LL; Kimer N; Krag A
    Aliment Pharmacol Ther; 2012 Oct; 36(7):619-26. PubMed ID: 22908905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Letter: Vaptans for the treatment of hyponatraemia and ascites in patients with cirrhosis.
    Karaahmet F; Coban S; Başar O; Yuksel O
    Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1103-4; author reply 1104. PubMed ID: 23130775
    [No Abstract]   [Full Text] [Related]  

  • 3. [Vasopressin receptor antagonists: the vaptans].
    Villabona C
    Endocrinol Nutr; 2010 May; 57 Suppl 2():41-52. PubMed ID: 21130961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic potential of vasopressin receptor antagonists.
    Ali F; Guglin M; Vaitkevicius P; Ghali JK
    Drugs; 2007; 67(6):847-58. PubMed ID: 17428103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review of known interventions for the treatment of chronic nonhypovolaemic hypotonic hyponatraemia and a meta-analysis of the vaptans.
    Bhandari S; Peri A; Cranston I; McCool R; Shaw A; Glanville J; Petrakova L; O'Reilly K
    Clin Endocrinol (Oxf); 2017 Jun; 86(6):761-771. PubMed ID: 28214374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial.
    Ginès P; Wong F; Watson H; Milutinovic S; del Arbol LR; Olteanu D;
    Hepatology; 2008 Jul; 48(1):204-13. PubMed ID: 18508290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The treatment of vasopressin V2-receptor antagonists in cirrhosis patients with ascites: a meta-analysis of randomized controlled trials.
    Yan L; Xie F; Lu J; Ni Q; Shi C; Tang C; Yang J
    BMC Gastroenterol; 2015 Jun; 15():65. PubMed ID: 26054761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerance of urea compared with vaptans for long-term treatment of patients with SIADH.
    Soupart A; Coffernils M; Couturier B; Gankam-Kengne F; Decaux G
    Clin J Am Soc Nephrol; 2012 May; 7(5):742-7. PubMed ID: 22403276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis.
    Wong F; Gines P; Watson H; Horsmans Y; Angeli P; Gow P; Minini P; Bernardi M
    J Hepatol; 2010 Aug; 53(2):283-90. PubMed ID: 20541828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Satavaptan treatment for ascites in patients with cirrhosis: a meta-analysis of effect on hepatic encephalopathy development.
    Watson H; Jepsen P; Wong F; Ginès P; Córdoba J; Vilstrup H
    Metab Brain Dis; 2013 Jun; 28(2):301-5. PubMed ID: 23463488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic potential of vasopressin-receptor antagonists in heart failure.
    Izumi Y; Miura K; Iwao H
    J Pharmacol Sci; 2014; 124(1):1-6. PubMed ID: 24401675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity.
    Wong F; Watson H; Gerbes A; Vilstrup H; Badalamenti S; Bernardi M; Ginès P;
    Gut; 2012 Jan; 61(1):108-16. PubMed ID: 21836029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of hyponatremia: the role of lixivaptan.
    Liamis G; Filippatos TD; Elisaf MS
    Expert Rev Clin Pharmacol; 2014 Jul; 7(4):431-41. PubMed ID: 24766294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH).
    Gassanov N; Semmo N; Semmo M; Nia AM; Fuhr U; Er F
    Eur J Clin Pharmacol; 2011 Apr; 67(4):333-346. PubMed ID: 21327910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The treatment of hyponatraemia using vasopressin antagonists.
    Gross P; Palm C
    Exp Physiol; 2000 Mar; 85 Spec No():253S-257S. PubMed ID: 10795929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients.
    Zhang X; Wang SZ; Zheng JF; Zhao WM; Li P; Fan CL; Li B; Dong PL; Li L; Ding HG
    World J Gastroenterol; 2014 Aug; 20(32):11400-5. PubMed ID: 25170228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hyponatremic hypervolemia in heart failure--the hot spot for vasopressin receptor antagonists?].
    Dabrowska MD; Krysiak R; Okopień B
    Wiad Lek; 2012; 65(1):19-30. PubMed ID: 22827112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Vasopressin antagonists in treatment of hyponatremia].
    Olszewski W; Głuszek J
    Pol Arch Med Wewn; 2007 Aug; 117(8):356-62. PubMed ID: 18018383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of hyponatremia in clinical hepatology practice.
    Kwo PY
    Curr Gastroenterol Rep; 2014; 16(5):382. PubMed ID: 24659251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Vasopressin receptor antagonists and heart failure].
    Haass M
    Ther Umsch; 2009 Nov; 66(11):735-40. PubMed ID: 19885790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.